[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE9304060D0 - Sätt att selektera specifika bakteriofager - Google Patents

Sätt att selektera specifika bakteriofager

Info

Publication number
SE9304060D0
SE9304060D0 SE9304060A SE9304060A SE9304060D0 SE 9304060 D0 SE9304060 D0 SE 9304060D0 SE 9304060 A SE9304060 A SE 9304060A SE 9304060 A SE9304060 A SE 9304060A SE 9304060 D0 SE9304060 D0 SE 9304060D0
Authority
SE
Sweden
Prior art keywords
phage
pct
molecule
protein
methods
Prior art date
Application number
SE9304060A
Other languages
English (en)
Inventor
Carl A K Borrebaeck
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Priority to SE9304060A priority Critical patent/SE9304060D0/sv
Publication of SE9304060D0 publication Critical patent/SE9304060D0/sv
Priority to CA002178205A priority patent/CA2178205A1/en
Priority to AT95903485T priority patent/ATE178092T1/de
Priority to JP51614195A priority patent/JP3574135B2/ja
Priority to EP95903485A priority patent/EP0739413B1/en
Priority to DE69417446T priority patent/DE69417446T2/de
Priority to AU12521/95A priority patent/AU686292B2/en
Priority to ES95903485T priority patent/ES2132601T3/es
Priority to DK95903485T priority patent/DK0739413T3/da
Priority to US08/640,792 priority patent/US5712089A/en
Priority to PCT/SE1994/001166 priority patent/WO1995016027A1/en
Priority to GR990401295T priority patent/GR3030210T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9304060A 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager SE9304060D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager
PCT/SE1994/001166 WO1995016027A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
EP95903485A EP0739413B1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
AT95903485T ATE178092T1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
JP51614195A JP3574135B2 (ja) 1993-12-06 1994-12-05 特異的バクテリオファージの選択方法
CA002178205A CA2178205A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
DE69417446T DE69417446T2 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
AU12521/95A AU686292B2 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
ES95903485T ES2132601T3 (es) 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos.
DK95903485T DK0739413T3 (da) 1993-12-06 1994-12-05 Fremgangsmåde til udvælgelse af specifikke bakteriofager
US08/640,792 US5712089A (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
GR990401295T GR3030210T3 (en) 1993-12-06 1999-05-13 Method of selecting specific bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
SE9304060D0 true SE9304060D0 (sv) 1993-12-06

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Country Status (12)

Country Link
US (1) US5712089A (sv)
EP (1) EP0739413B1 (sv)
JP (1) JP3574135B2 (sv)
AT (1) ATE178092T1 (sv)
AU (1) AU686292B2 (sv)
CA (1) CA2178205A1 (sv)
DE (1) DE69417446T2 (sv)
DK (1) DK0739413T3 (sv)
ES (1) ES2132601T3 (sv)
GR (1) GR3030210T3 (sv)
SE (1) SE9304060D0 (sv)
WO (1) WO1995016027A1 (sv)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
MXPA00007889A (es) * 1998-02-11 2002-09-18 Maxygen Inc Optimizacion de las propiedades inmunomoduladoras de las vacunas geneticas.
EP1518927A3 (en) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
WO2001044463A1 (en) * 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
US6686154B2 (en) * 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
PT1303293E (pt) 2000-07-27 2009-03-11 Genentech Inc Administração sequencial de cpt-11 e polipéptido apo-2l
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
ATE356871T1 (de) * 2002-05-17 2007-04-15 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
KR101388611B1 (ko) 2002-10-16 2014-04-23 퍼듀 퍼머 엘피 세포-연관된 ｃａ 125/ｏ772ｐ에 결합하는 항체들 및 그것의 용도의 방법들
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
SI3031825T1 (sl) 2008-03-14 2019-12-31 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
MX2010014358A (es) 2008-06-20 2011-07-04 Wyeth Llc Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas.
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
EP3199630B1 (en) * 2008-09-05 2019-05-08 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
SI3281953T1 (sl) 2009-03-13 2020-03-31 Allergan, Inc. Na imunosti temelječi testi za aktivnosti ponovno ciljane endopeptidaze
CA2807244A1 (en) * 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
AU2011348204B2 (en) * 2010-12-22 2017-03-02 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2014150870A2 (en) 2013-03-15 2014-09-25 Altria Client Services Inc. Bacteriophage and methods of making and using
CA2932788A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
IL290972B2 (en) 2013-12-24 2023-10-01 Janssen Pharmaceutica Nv Antibodies and anti-VISTA fragments
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
US9781929B2 (en) 2015-01-29 2017-10-10 Altria Client Services Llc Bacteriophage and methods of using
WO2016123425A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Endolysin from bacteriophage against geobacillus and methods of using
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and uses thereof
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
MA46366A (fr) 2016-09-30 2019-08-07 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
KR20240065333A (ko) 2016-11-16 2024-05-14 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
EP3573658A4 (en) 2017-01-30 2021-07-21 Janssen Biotech, Inc. ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
AU2017398101B2 (en) 2017-02-07 2025-02-06 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
JP2020534025A (ja) 2017-08-25 2020-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ＢｏＮＴペプチダーゼの進化
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
CA3113837C (en) 2018-09-24 2022-07-12 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
CN113574066A (zh) 2019-01-15 2021-10-29 詹森生物科技公司 用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法
CN113330031A (zh) 2019-01-23 2021-08-31 詹森生物科技公司 用于在治疗银屑病关节炎的方法中使用的抗tnf抗体组合物
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
US12129292B2 (en) 2019-03-14 2024-10-29 Janssen Biotech, Inc. Anti-tumor necrosis factor (TNF) antibodies and compositions thereof
US20200291107A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
US20200331996A1 (en) 2019-03-18 2020-10-22 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3976648A1 (en) 2019-06-03 2022-04-06 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CN117751138A (zh) 2021-03-12 2024-03-22 詹森生物科技公司 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
MX2023010697A (es) 2021-03-12 2023-11-23 Janssen Biotech Inc Método para tratar pacientes con artritis psoriásica con respuesta inadecuada a la terapia de tnf con anticuerpo específico anti-il23.
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3239216A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (en) * 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins

Also Published As

Publication number Publication date
DE69417446T2 (de) 1999-09-02
DK0739413T3 (da) 1999-10-11
JPH09506000A (ja) 1997-06-17
GR3030210T3 (en) 1999-08-31
WO1995016027A1 (en) 1995-06-15
US5712089A (en) 1998-01-27
AU1252195A (en) 1995-06-27
ATE178092T1 (de) 1999-04-15
ES2132601T3 (es) 1999-08-16
CA2178205A1 (en) 1995-06-15
EP0739413B1 (en) 1999-03-24
JP3574135B2 (ja) 2004-10-06
DE69417446D1 (de) 1999-04-29
AU686292B2 (en) 1998-02-05
EP0739413A1 (en) 1996-10-30

Similar Documents

Publication Publication Date Title
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69833106D1 (de) Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten.
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
FI854187A0 (fi) Immunoanalyser foer denaturerade proteinanalyser, saerskilt hb alc, samt antikroppar anvaendbara i dessa.
DK0626861T3 (da) Behandling af astma.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
ATE147406T1 (de) Synthetisches cdw52(campath-1) peptidantigen
ATE111606T1 (de) Ein gattungsspezifisches listeria-antigen, identifiziert durch monoklonale antikörper.
HUT69623A (en) Use of endotheli- leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
DE59611353D1 (de) Transketolase-verwandtes protein
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk